Clinical Trials Sponsored by Merck Foundation

Total 20659 results

PETHEMA Foundation
Merck Sharp & Dohme LLC

Completed

AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors (AMENO-2)

Lymphoma | Leukemia

Spain
NEAT ID Foundation
Merck Sharp & Dohme LLC

Completed

A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/ (DrEW)

HIV I Infection

France, United Kingdom
RTOG Foundation, Inc.
Merck Sharp & Dohme LLC

Recruiting

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)

Head and Neck Squamous Cell Carcinoma (HNSCC)

Canada, United States
Merck Sharp & Dohme LLC
Cystic Fibrosis Foundation

Completed

Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease

Cystic Fibrosis
Fundacion GESICA
Merck Sharp & Dohme LLC

Recruiting

A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires

Flavivirus Infections | Dengue

Argentina
Mercy Medical Center
First Candle Foundation

Completed

Promoting Fetal Movement Monitoring: Improving Birth Outcomes

Fetal Kick Counting

United States
Alliance Foundation Trials, LLC.
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

United States
Alliance Foundation Trials, LLC.
Merck Sharp & Dohme LLC

Completed

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

Non-Small Cell Lung Cancer

United States
OncoC4, Inc.
Merck Sharp & Dohme LLC; GOG Foundation

Recruiting

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

United States
ETOP IBCSG Partners Foundation
Merck Sharp & Dohme LLC; Frontier Science Foundation, Hellas

Completed

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma (PROMISE-meso)

Pleural Mesothelioma Malignant Advanced

United Kingdom, Switzerland, Spain
Fundacion SEIMC-GESIDA
Merck Sharp & Dohme LLC

Completed

A Clinical Trial to Evaluate the Immunogenicity of the Nonavalent Vaccine Against Human Papillomavirus in Men Infected by HIV Who Have Sex With Men. GESIDA 10017 (GESIDA10017)

HIV Infections

Spain
Children's Mercy Hospital Kansas City
Merck Sharp & Dohme LLC

Completed

Montelukast in the Treatment of Duodenal Eosinophilia

Dyspepsia | Eosinophilic Gastroenteritis

United States
Fundacion SEIMC-GESIDA
Merck Sharp & Dohme LLC

Completed

Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence. (BEFORE)

Clostridium Difficile Infection

Spain
Fundacion SEIMC-GESIDA
Merck Sharp & Dohme LLC

Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression (GENIS)

HIV Infections | Severe Immunosuppression

Spain
Indiana University
Merck Sharp & Dohme LLC; National Kidney Foundation

Completed

The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

Chronic Kidney Disease | Dialysis

United States
Royal Marsden NHS Foundation Trust
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Phase I Study Compound 451238 and Radiotherapy in Soft-tissue Sarcoma

Soft-tissue Sarcoma

United Kingdom
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma (GEMMK)

Sarcoma

United Kingdom
The Christie NHS Foundation Trust
Merck Sharp & Dohme LLC

Completed

Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy (eSCOUT)

Metastatic Colorectal Cancer

United Kingdom
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC

Terminated

PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients (PRIMING)

Metastatic Non-small-cell lunG Cancer

United Kingdom
Papworth Hospital NHS Foundation Trust
Merck Sharp & Dohme LLC

Completed

Serum Bio-markers in Pulmonary Hypertension

Pulmonary Hypertension, Primary, 4

United Kingdom
PETHEMA Foundation
Merck Sharp & Dohme LLC; Adknoma Health Research

Completed

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Multiple Myeloma

Spain
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC

Withdrawn

A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM) (ADAPTeM)

Advanced Melanoma
Royal Marsden NHS Foundation Trust
Merck Serono International SA

Terminated

A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU) (PERU)

Pancreatic Cancer

United Kingdom
University Hospital, Bordeaux
Merck Serono International SA; ARSEP foundation

Completed

Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis (REACTIV)

Multiple Sclerosis | Cognitive Rehabilitation

France
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma (MESO-PRIME)

Advanced Malignant Pleural Mesothelioma

United Kingdom
Royal Marsden NHS Foundation Trust
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC)

Gastric Adenocarcinoma | Oesophageal Adenocarcinoma

United Kingdom
Jhpiego
Bill and Melinda Gates Foundation; Merck for Mothers

Completed

Postpregnancy Family Planning Choices in Public and Private Sectors in Kenya and Indonesia (PPFP Choices)

Post-pregnancy Family Planning | Capacity Building of Healthcare Providers

Indonesia
Merck KGaA, Darmstadt, Germany
Merck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaborators

Completed

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR) (STAR)

Multiple Sclerosis, Relapsing Remitting

Greece
UNICANCER
Merck Sharp & Dohme LLC; Fondation ARC; ERA-NET

Active, not recruiting

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations (PEVOsq)

Vulvar Cancer | Cervix Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Penile Cancer | Squamous Cell Lung Cancer

France
Regenstrief Institute, Inc.
Merck Sharp & Dohme LLC; National Sleep Foundation

Unknown

Testing Utility of Commercially Available Sleep Trackers for Physician-Patient Communication

Insomnia

United States
University Hospital Birmingham NHS Foundation Trust
Merck Sharp & Dohme LLC

Recruiting

Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis (REACTIVAS)

ANCA Associated Vasculitis

United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Merck Sharp & Dohme LLC

Completed

MRE as a Screening Tool for axSpA in IBD (ProSpA-CD)

Crohn Disease | Axial Spondyloarthritis

United Kingdom
Chelsea and Westminster NHS Foundation Trust
Merck Sharp & Dohme LLC

Recruiting

The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients (META-D)

Hiv

United Kingdom
NuGenerex Immuno-Oncology
Merck Sharp & Dohme LLC; NSABP Foundation Inc

Active, not recruiting

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

Triple-negative Breast Cancer

United States
Children's Mercy Hospital Kansas City
The Gerber Foundation

Enrolling by invitation

CHAMP For the Feeder: Tube Feeding Study

Feeding Disorders

United States
Children's Mercy Hospital Kansas City
The Gerber Foundation

Enrolling by invitation

CHAMP App Feeding Difficulties Repository

Feeding and Eating Disorders of Childhood | Gastrostomy | Feeding Disorder of Infancy and Childhood

United States
Mercy Health System
Rockford Memorial Hospital Development Foundation

Terminated

The Effects of Probiotic Supplementation on Extremely Low Birthweight Infants

Feeding Tolerance

United States
Merck KGaA, Darmstadt, Germany
Merck Serono GmbH, Germany; Merck B.V., Netherlands; Merck A.E., Greece; Merck... and other collaborators

Completed

PERgoveriS In Stratified Treatment for Assisted Reproductive Technique (PERSIST)

Assisted Reproductive Techniques | Reproductive Technology, Assisted

Italy, Russian Federation, United Kingdom, Germany, Poland, Finland, Slovakia, Netherlands, Denmark, France, Greece
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea (PRISM)

Heart Failure, Congestive

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)

Infertility

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control (GIANT)

Hypertension | Diabetes Mellitus, Type II

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])

Hypertension

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients. (ABBA)

Chronic Heart Failure

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Completed

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in South Korea (ECOS KOR)

Growth Disorders

Korea, Republic of
Merck KGaA, Darmstadt, Germany
Merck Ltd.

Terminated

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Colorectal Neoplasm

Korea, Republic of
NSABP Foundation Inc
Eli Lilly and Company; Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Metastatic Colorectal Cancer

United States
University of California, San Francisco
Merck Sharp & Dohme LLC; Avon Foundation

Terminated

Reversing Therapy Resistance With Epigenetic-Immune Modification

Breast Neoplasms

United States
Royal Marsden NHS Foundation Trust
Merck KGaA, Darmstadt, Germany; 4SC AG

Unknown

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) (EMERGE)

Cancer | GI Cancer

United Kingdom
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Active, not recruiting

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Metastatic Castration-resistant Prostate Cancer

China

Clinical Trials Sponsored by Merck Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations